Status:
COMPLETED
Remotely Supervised tDCS for Slowing ALS Disease Progression
Lead Sponsor:
University of Illinois at Chicago
Collaborating Sponsors:
University of Chicago
Conditions:
Amyotrophic Lateral Sclerosis (ALS)
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Most ALS care is centered on patient support and symptom management, making rehabilitation an integral aspect for slowing disease progression, prolonging life span, and increasing quality of life. Bra...
Eligibility Criteria
Inclusion
- Diagnosis of possible, probable, or definite amyotrophic lateral sclerosis according to El Escorial revised criteria
- Spinal onset ALS with initial weakness in the upper or lower extremity.
- Diagnosed with ALS within the past 5 years
- 1-2 point change in pre-slope of the ALSFRS-R at time of enrollment (ratio of drop in score from 48 to the duration in months from onset of weakness)
- Score ≥ 2 for "swallowing" of the ALSFRS-R
- Score ≥ 2 for "walking" of the ALSFRS-R
- Able to provide informed consent
- Stable dose of riluzole, edaravone, AMX0035 (Relyvrio) or no medications
- Availability of a caregiver for remote administration of tDCS
Exclusion
- Subject has bulbar onset ALS
- Any neurological diagnosis other than ALS
- Psychiatric disorders
- Any other concomitant disease that affects prognosis of ALS inclusive of systemic disease, cardiovascular disease, hepatic or renal disorder
- Tracheostomal or noninvasive ventilation for more than 12 hours per day
- Enrollment in an on-going ALS pharmaceutical trial
- Subject plans on moving within 6 months.
- TMS
Key Trial Info
Start Date :
August 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT04866771
Start Date
August 27 2021
End Date
January 1 2025
Last Update
August 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brain Plasticity Lab
Chicago, Illinois, United States, 60305